Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Drug Deliv ; 18(1): 46-53, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20726805

RESUMO

To develop a novel flurbiprofen-loaded solid dispersion without crystalline change, various flurbiprofen-loaded solid dispersions were prepared with water, sodium carboxylmethyl cellulose (Na-CMC), and Tween 80. The effect of Na-CMC and Tween 80 on aqueous solubility of flurbiprofen was investigated. The physicochemical properties of solid dispersions were investigated using SEM, DSC, and X-ray diffraction. The dissolution and bioavailability in rats were evaluated compared to commercial product. Unlike conventional solid dispersion systems, the flurbiprofen-loaded solid dispersion gave a relatively rough surface and changed no crystalline form of drug. These solid dispersions were formed by attaching hydrophilic carriers to the surface of drug without crystal change, resulting in changing the hydrophobic drug to hydrophilic form. Furthermore, the flurbiprofen-loaded solid dispersion at the weight ratio of flurbiprofen/Na-CMC/Tween 80 of 6/2.5/0.5 improved ~60-fold drug solubility. It gave higher AUC, T(max), and C(max) compared to commercial product. The solid dispersion improved almost 1.5-fold bioavailability of drug compared to commercial product in rats. Thus, the flurbiprofen-loaded solid dispersion would be useful to deliver poorly water-soluble flurbiprofen with enhanced bioavailability without crystalline change.


Assuntos
Anti-Inflamatórios não Esteroides/química , Portadores de Fármacos/química , Flurbiprofeno/química , Administração Oral , Animais , Anti-Inflamatórios não Esteroides/farmacocinética , Área Sob a Curva , Disponibilidade Biológica , Varredura Diferencial de Calorimetria , Carboximetilcelulose Sódica/química , Química Farmacêutica/métodos , Formas de Dosagem , Portadores de Fármacos/farmacocinética , Flurbiprofeno/farmacocinética , Interações Hidrofóbicas e Hidrofílicas , Cristais Líquidos/química , Masculino , Microscopia Eletrônica de Varredura , Polissorbatos/química , Ratos , Ratos Sprague-Dawley , Solubilidade , Comprimidos/síntese química , Comprimidos/química , Água/química , Difração de Raios X
2.
Int J Pharm ; 400(1-2): 145-52, 2010 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-20826201

RESUMO

To develop a novel combination tablet which contained 100 mg trimebutine maleate and 5 mg mosapride citrate (TMCT) for the treatment of functional dyspepsia, the wet granulation method was used to prepare TMCTs with various amounts of diluents and stabilizers. The levels of impurities, the stability and the dissolution of the TMCTs were investigated. The oral bioavailability of drugs in the TMCTs was then evaluated and compared to the simultaneous oral administration of trimebutine maleate-loaded and mosapride citrate-loaded commercial products in the beagle dog. Among the diluents tested, D-mannitol was selected, since the microcrystalline cellulose and lactose did not inhibit the production of drug impurities due to their hygroscopic properties and chemical interactions, respectively. Furthermore, succinic acid was selected as the stabilizer because it gave the lowest level of total drug impurities of the organic acids tested. The combination tablet of trimebutine maleate and mosapride citrate prepared with D-mannitol and succinic acid gave a total drug content higher than 95% and total impurities lower than 0.5% at 25°C/60% RH and 40°C/75% RH during a 6-month period, indicating that the tablets were stable for at least 6 months. Furthermore, this combination tablet showed a similar dissolution to the trimebutine maleate-loaded and mosapride citrate-loaded commercial products and gave insignificantly different absorption compared to these commercial products in beagle dogs. Thus, the combination tablet of trimebutine maleate and mosapride citrate prepared with D-mannitol and succinic acid would be a stable and effective oral pharmaceutical product for the treatment of functional dyspepsia.


Assuntos
Benzamidas/farmacocinética , Dispepsia/tratamento farmacológico , Fármacos Gastrointestinais/farmacocinética , Morfolinas/farmacocinética , Trimebutina/farmacocinética , Animais , Benzamidas/química , Benzamidas/uso terapêutico , Disponibilidade Biológica , Cães , Combinação de Medicamentos , Composição de Medicamentos , Estabilidade de Medicamentos , Excipientes/química , Fármacos Gastrointestinais/química , Fármacos Gastrointestinais/uso terapêutico , Masculino , Manitol/química , Morfolinas/química , Morfolinas/uso terapêutico , Solubilidade , Ácido Succínico/química , Comprimidos , Trimebutina/química , Trimebutina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA